DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/23fccd/fabrys_disease_th) has announced the addition of GlobalData's new report "Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Fabry's Disease Therapeutics market. The report identifies the key trends shaping and driving the global Fabry's Disease Therapeutics market.
The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Fabry's Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Fabry's Disease Therapeutics Market is Forecast to Witness Significant Growth until 2018
GlobalData estimates that the global Fabry's disease therapeutics market grew at a compound annual growth rate (CAGR) of 9.9% during 2005-2010 and was worth $412.8m in 2010. The market is expected to record a CAGR of 12.8% from 2010-2018, to reach a value $1,078.8m by 2018. Currently, enzyme replacement therapy (ERT) is the major available therapy for Fabry patients. The ERT class includes Fabrazyme (agalsidase beta) of Genzyme (a Sanofi company) and Replagal (agalsidase alfa) of Shire as approved products.
Fabrazyme has been marketed in the European region since 2001, in the US since 2003, and in Japan since 2004. Fabrazyme has also received marketing approval in 44 countries, commercial sales in 31 countries, and in addition several post-marketing commitments are also ongoing. Replagal has been approved in the European region since 2001 and in Japan since February 2007. Replagal has yet to be approved in the US.
Companies Mentioned:
- GlaxoSmithKline
- Amicus
For more information visit http://www.researchandmarkets.com/research/23fccd/fabrys_disease_th